We rank Rugiet against the focused men's-health ED challengers — the set it actually competes with on product — on the same 0–100 structural-advantage scale. The 3-in-1 dissolvable tablet is the most genuinely novel product among them, which lifts Rugiet to 46, above its macro standing and ahead of the unbranded long tail. The same three constraints hold it back in every comparison: undisclosed scale, an efficacy claim that reads as marketing, and the deepest compounded-drug liability. Hover any bar to read the challenger.
The 3-in-1 dissolvable tablet — sildenafil, tadalafil, and apomorphine, company-asserted onset near fifteen minutes — is the most novel product in the focused set, which is why Rugiet scores higher here (46) than against the broad market (40). The novelty is also being matched: Medvi markets a four-drug compounded product (sildenafil, tadalafil, vardenafil, and apomorphine itself), so the apomorphine wedge is one competitors already chase, carrying the same unapproved-for-ED safety baggage. Hims and Ro clear the field on owned acquisition and capital; Rex MD and BlueChew win on price discipline and recall. The formulation is real, and the wedge it cuts is narrow. Ahead only of the unbranded long tail.
Hims (Sexual Health) tops the focused set at 90 on $100M+ sexual-health revenue and owned 503B manufacturing — the benchmark no focused challenger matches. Roman follows at 82 on the strongest unaided recall and multi-condition retention. Rex MD at 63 is profitable with ~215K active patients and new compounded lines in H1 2026; BlueChew at 58 carries the most recognizable focused-challenger brand on chewable-format differentiation and creator advertising. Rugiet lands at 46 — the most novel formulation in the set, a 3-in-1 compounded dissolvable tablet adding apomorphine, company-asserted pricing from ~$7.29/dose — held back by undisclosed scale, an efficacy claim that rests on marketing, and the deepest compounded-drug exposure. It sits ahead only of the smaller compounded and personalized-dose challengers at 38, the long tail that anchors the floor. The formulation lifts the floor; it does not clear the field.